A Clear Advantage over Mono and Combination Therapy- Antibody Drug Conjugates (ADCs)
Antibody Drug Conjugates (ADCs) are turning into an undeniably imperative sub-class of antibody-related therapeutics. Two ADCs, brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla), were as of late affirmed for marketing both by the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA).
View full press release